Cohava Gelber, Ph.D., M.B.A.

Biosketch

Cohava Gelber, PhD, MBA, is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. Dr. Gelber held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation).
Dr. Gelber has recently launched Caerus Discovery, LLC (CDL) with support from Biowa/ Kyowa Hakko Kirin.  CDL ‘s mission is to discover and develop new antibody-based therapeutics and diagnostics.  Prior to founding CDL, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC, VP of R&D for MannKind Corp- a public company developing therapeutics for diabetes, cancer and autoimmune diseases and was responsible for non-clinical development and clinical immune safety of drugs from pre IND through phase III clinical trials. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University.
Dr. Gelber published numerous scientific manuscripts and textbook chapters and she is the inventor of 16 granted patents and 57 patent applications.

Research Interests

Therapeutic and diagnostic antibody development, subtractive immunization, biomarker discovery.


Selected publications:
  1. G.H. Wheatley III, K.P. McKinnon, M. Iacobucci, S. Mahon, C. Gelber, and H.K. Lyerly.  Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of post transplantation lymphoma, 1998.  Surgery.  124(2): 171-176.
  2. P. Krueger, C. Nitz, J. Moore, R. Foster, O. Gelber, and C. Gelber.  Monoclonal Antibody Identifies a Distinctive Epitope Expressed by Human Multiple Myeloma Cells, 2001.  Journal of Immunotherpy.  24(4): 334-344.
  3. P. Kueger, C. Nitz, R. Foster, C. MacDonald, O. Gelber, G. Lalehzadeh, R. Goodson, J. Winter, and C. Gelber.  A new small cell lung cancer (SCLC) specific marker discovered through antigenic subtraction of neuroblastoma cells, 2003.  Cancer Immunology, Immunotherapy, Volume 52, Issue 6, pp 367-377.
  4. P. Krueger, K. Daukas, P. Menkin, I. Trantcheva, M. Jackson, T. Vaccaro, K. Rousseau, I. Carballo, O. Gelber, M. Grant, And C. Gelber. The Pharmacokinetic Profile of Technosphere®/ Insulin Administered by Inhalation in the Rat Model.  American Association for Diabetes Research Proceedings, 2004.
  5. M. Grant, P. Menkin, I. Trantcheva, K. A. Leiner, and C. Gelber. The Distribution of 14C-labeled Technosphere® Particles Following Intra-tracheal, Liquid Instillation in the Sprague-Dawley Rat. American Association for Diabetes Research Proceedings, 2004.
  6. P. Krueger, K. Rousseau, I. Carballo, L. Harris, R. Wood, and C. Gelber.  Technosphere® Matrix: A Novel Pulmonary Drug Delivery Agent. American Association for Diabetes Research Proceedings, 2004.
  7. J. Simms, C. Auge, S. Weksler-Zangen, J. Schmidt, A. Chung, S. Hacohen, S. Klein, I. Raz, and C. Gelber. Characterization of Differentially Expressed Protein Biomarkers in Pancreatic Tissues Derived from the Cohen Diabetic Rat Model of Type 2 Diabetes. American Association for Diabetes Research Proceedings, 2007.
  8. Novel Biomarkers Identified by Protein Profiling: Potential New Diagnosis and Therapeutics for Type 2 Diabetes. Liping Liu, Zhidong Xie, Sarah Zangen, Raquel Manteiga, Shelley Hacohen, Wendell Cheatham, Itamar Raz and Cohava Gelber. 2007 EASD proceedings.
  9. Transcriptome Analyses Reveals Potential Novel Biomarkers for the Development of Type 2 Diabetes. P. Ikonomi, S. Zangen, Q. Li, S. Hacohen, I. Raz2, C. Gelber.  2007 EASD proceedings.
  10. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?  Peyton Hughes, Damian Marshall, Yvonne Reid, Helen Parkes, and Cohava Gelber. BioTechniques 43:575-586 (November 2007).
  11. CANCER BIOMARKERS: Proteome analysis of pancreatic cancer tissue for identification of novel biomarkers; Ganepola Ganepola, Paritosh Suman, and Cohava Gelber  Cancer Res., Dec 2009; 69: C32.
Issued Patents
No Patent No Title Published
1 US 7498129

Myeloma cell and ovarian cancer cell surface glycoproteins,

antibodies thereto, and uses thereof
Mar 3, 2009
2 US 7691376

Ovarian cancer cell and myeloma cell surface glycoproteins,

antibodies thereto, and uses thereof
Apr 6, 2010
3 US 7435415

Monoclonal antibodies and cell surface antigens for the

detection and treatment of small cell lung cancer (SCLC)
Oct 14, 2008
4 EP 1204683 B1

OVARIAN CANCER CELL AND MYELOMA CELL

SURFACE GLYCOPROTEINS, ANTIBODIES THERETO,
AND USES THEREOF
Jun 22, 2011
5 US 7687607

Monoclonal antibodies and cell surface antigens for the detection

and treatment of small cell lung cancer (SCLS)
Mar 30, 2010
6 US 6986891

Myeloma cell and ovarian cancer cell surface glycoproteins,

antibodies thereto, and uses thereof
Jan 17, 2006
7 US 7183389

Monoclonal antibodies and cell surface antigens for the

detection and treatment of small cell lung cancer (SCLC)
Feb 27, 2007
8 US 6991779

Compositions for treatment or prevention of bioterrorism Jan 31, 2006
9 US 7951382

Methods for treatment of type 2 diabetes May 31, 2011
10 AU 2003/257156 B2

Cell transport compositions and uses thereof Aug 30, 2007
11 EP 1350085 B1

MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS

FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
Dec 31, 2008
12 US 7435554

Monoclonal antibodies and cell surface antigens for the

detection and treatment of small cell lung cancer (SCLC)
Oct 14, 2008
13 AU 756951 B2

Methods and devices for modulating the immune response Jan 30, 2003
14 US 7951776

Methods for treatment of type 1 diabetes May 31, 2011
15 US 6376654

Myeloma cell and ovarian cancer cell surface glycoproteins,

antibodies thereto, and uses thereof
Apr 23, 2002
16 US 7226750

Ovarian cancer cell and myeloma cell surface glycoproteins,

antibodies thereto, and uses thereof
Jun 5, 2007